Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

Categories: Summer/Fall 2021

There are many treatments available for men presenting with newly-diagnosed metastatic prostate cancer, but it is unclear how they compare for their effectiveness, safety, and costs. Dr. Lin Wang and associates searched large databases in the published literature from randomized clinical trials through November 2019, to compare the effectiveness and safety of the many available treatments, including hormonal therapy and chemotherapy.

Seven trials including 7,287 patients comparing six treatments were identified. The results suggested that as treatments that could be added to standard hormonal therapy, abiraterone acetate (Zytiga®) and apalutamide (Erleada®) may provide the largest overall survival benefits with relatively low serious adverse side effects. Although enzalutamide (Xtandi®) -reduced disease progression to the greatest extent, it may be associated with more fatigue, and longer follow-up is needed to examine its overall survival benefits.

 

Wang, L et al JAMA Oncol PMID: 33443584

 

RELATED QUEST ARTICLES

POPULAR QUEST ARTICLES

RECENT QUEST ARTICLES

Subscribe to Quest

"*" indicates required fields

Email*

This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*
Address*